Article
The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
BMC cancer - 26 Oct 2019
Fernández-Navarro Pablo, López-Nieva Pilar, Piñeiro-Yañez Elena, Carreño-Tarragona Gonzalo, Martinez-López Joaquín, Sánchez Pérez Raúl, Aroca Ángel, Al-Shahrour Fátima, Cobos-Fernández María Ángeles, Fernández-Piqueras José
Abstract excerpt
BACKGROUND: Acute T-cell lymphoblastic leukaemia (T-ALL) is an aggressive disorder derived from immature thymocytes. The variability observed in clinical responses on this type of tumours to treatments, the high toxicity of current protocols and the poor prognosis of patients with relapse or refractory make it urgent to find less toxic and more effective therapies in the context of a personalized medicine of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
